Abstract 4828
Background
Metastatic disease to the lung is one of the most common life-threatening complications of cancer and can be seen with most types of cancer. Apatinib, a tyrosine kinase inhibitor targeting VEGFR-2, has shown efficacy in lung cancer. And the preclinical data also showed plasma concentration of apatinib was high in the lung. This cancer registry study aims to make an exploratory assessment of the efficacy and safety of apabinib in lung metastases.
Methods
Between 2015/05 and 2018/03, this study recorded all patients with advanced cancers in our hospital, with apatinib 500 mg or 250 mg being given. Tumor response assessment and survival analysis were performed.
Results
For a total of 103 patients, 30 had no lung metastases, and 73 had lung metastases, among which most were bone sarcoma (56%) and soft-tissue sarcoma (37%) metastases to lung. Among 57 evaluable patients with lung metastases, 2 achieved CR, 29 achieved PR, and the ORR was 54%. In 11 evaluable patients with no lung metastases, no patient achieved CR, 3 patients achieved PR, and the ORR was 27%. For patients with lung metastases, the mPFS was 12.9 months (95%CI, 8.6-14.9 months), mOS was 21.9 months (95% CI, 15.9-31.3 months). For patients with no lung metastases, the mPFS was 6.0 months (95%CI, 4.6-NE months), the mOS was 10.7 months (95% CI, 5.2-NE months). In lung metastatic patients who received apatinib 500mg, the ORR and DCR were, respectively, 55.1% and 89.8%; when treated with apatinib 250mg, the ORR and DCR were 20% and 80%. When Apatinib was used as first line treatment, the ORR and DCR were respectively 64% and 88%; in second line treatment, the ORR and DCR were respectively 42% and 84%, and when apatinib was used in third line treatment, the ORR and DCR were 33% and 100%. For patients with lung metastases, 89.2% patients experienced adverse events (AEs); the most frequent AEs were hand-foot syndrome (21.6%), diarrhea (20%), hypertension (24.3%) and albuminuria (9.4%).
Conclusions
Based on this exploratory analysis, for bone sarcoma and soft-tissue sarcoma with lung metastases, apatinib 500mg showed promising trends in efficacy and safety profile. An expansion study will be needed.
Clinical trial identification
Legal entity responsible for the study
Chongqi Tu.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4942 - Analytical validation of OncoMasTR, a multigene test for predicting risk of distant recurrence in hormone receptor-positive early stage breast cancer
Presenter: Tony Loughman
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5641 - Comparing the prognosis of favourable-histology breast cancers between younger women of less than 45 years of age at diagnosis with their older counterparts.
Presenter: Guek Eng Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4448 - TNBC universe: a monocentric retrospective analyses of TILs and AR as prognostic markers
Presenter: Agnese Losurdo
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4755 - Genomic spectrum of Asian breast cancer based on targeted next-generation sequencing in 150 consecutive primary breast cancer
Presenter: Chihwan Cha
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2741 - The Impact of the 21 Gene Recurrence Score (RS) on Chemotherapy (CHemoRx) Prescribing in Hormone Receptor (HR) Positive, Lymph Node Positive (LN+) Early-Stage Breast Cancer (BC) in Ireland: A National, Multi-centre, Prospective Study (CTRIAL-IE 15-34)
Presenter: Anees Hassan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3356 - Lymphocyte-predominant breast cancer has a significant lower mean of absolute neutrophil counts compared to non-lymphocyte-predominant breast cancer: Analyses with 576 cases
Presenter: Da Young Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4020 - Genetic Alterations of Early-Stage Breast Cancers by next-generation sequencing (NGS)
Presenter: Yan Xu
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4924 - Oncotype Dx results in patients _40 years, Does age matters?: new insights
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2646 - Impact of BRCA status on outcomes and survival in high-risk early breast cancers
Presenter: Elodie Klajer
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4516 - Early breast cancer classified as intermediate risk by the Prosigna assay: Characteristics and treatment strategy
Presenter: Nawale Hajjaji
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract